tbuckley/cabot-search huggingface dataset:
Skin disorders and interstitial lung disease: Part II—The spectrum of cutaneous diseases with lung disease association
Authors: Lydia Ouchene, Anastasiya Muntyanu, Deborah Assayag, Èvicka Veilleux, Andy Abril, Giovanni Ferrara, Elaine Yacyshyn, Christian A. Pineau, Elizabeth O'Brien, Murray Baron, Mohammed Osman, Robert Gniadecki, Elena Netchiporouk
Journal: Journal of the American Academy of Dermatology (2022)
Differences in risk of tetracycline-associated hyperpigmentation between racial and ethnic groups in patients with acne vulgaris: A national US retrospective study
Authors: Katherine Young, Angel D. Pagan, Jaewon Yoon, Ethiopia Getachew, Bonnie Leung, Nga Nguyen, Arash Mostaghimi, Yevgeniy R. Semenov, Nicholas Theodosakis
Journal: Journal of the American Academy of Dermatology (2022)
Lipid nanomaterials-based RNA therapy and cancer treatment
Authors: Xingcai Zhang, Luo Hai, Yibo Gao, Guocan Yu, Yingli Sun
Journal: Acta Pharmaceutica Sinica B (2022)

We summarize the most important advances in RNA delivery and nanomedicine. We describe lipid nanoparticle-based RNA therapeutics and the impacts on the development of novel drugs. The fundamental properties of the key RNA members are described. We introduced recent advances in the nanoparticles to deliver RNA to defined targets, with a focus on lipid nanoparticles (LNPs). We review recent advances in biomedical therapy based on RNA drug delivery and state-of-the-art RNA application platforms, including the treatment of different types of cancer. This review presents an overview of current LNPs based RNA therapies in cancer treatment and provides deep insight into the development of future nanomedicines sophisticatedly combining the unparalleled functions of RNA therapeutics and nanotechnology.
Mitochondrial transplantation as a promising therapy for mitochondrial diseases
Authors: Tian-guang Zhang, Chao-yu Miao
Journal: Acta Pharmaceutica Sinica B (2022)

Mitochondrial diseases are a group of inherited or acquired metabolic disorders caused by mitochondrial dysfunction which may affect almost all the organs in the body and present at any age. However, no satisfactory therapeutic strategies have been available for mitochondrial diseases so far. Mitochondrial transplantation is a burgeoning approach for treatment of mitochondrial diseases by recovery of dysfunctional mitochondria in defective cells using isolated functional mitochondria. Many models of mitochondrial transplantation in cells, animals, and patients have proved effective via various routes of mitochondrial delivery. This review presents different techniques used in mitochondrial isolation and delivery, mechanisms of mitochondrial internalization and consequences of mitochondrial transplantation, along with challenges for clinical application. Despite some unknowns and challenges, mitochondrial transplantation would provide an innovative approach for mitochondrial medicine.
Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib
Authors: Adam S. Kittai, Ying Huang, Kyle A. Beckwith, Seema A. Bhat, David A. Bond, John C. Byrd, Daniel Goldstein, Michael R. Grever, Cecelia Miller, Kerry A. Rogers, Max Yano, Jennifer A. Woyach
Journal: American Journal of Hematology (2022)

Chronic lymphocytic leukemia (CLL) transformation to aggressive lymphoma, known as Richter's Transformation (RT), has a dismal prognosis. There are limited data evaluating risk of RT in patients treated with ibrutinib. We performed a retrospective analysis to determine prognostic variables associated with development of RT and overall survival (OS) at progression after treatment with ibrutinib. We identified 559 patients with CLL treated with ibrutinib from 2010-2019. After a median follow-up of 44.5 months from ibrutinib start, 179 patients progressed and were included in our analysis. After a median follow-up of 20.8 months from progression, 54 out of 179 patients developed RT. Progression on treatment (hazard ratio [HR] 4.01 [1.60-10.00], p = .003), higher LDH (HR 1.80 for 2-fold increase [1.33-2.43], p = .0001), and lymphadenopathy without lymphocytosis (HR 2.88 [1.15-7.20], p = .02) were independent prognostic variables for the development of RT at progression. Progression with lymphadenopathy without lymphocytosis continued to be an independent prognostic variable of worse OS post-progression. In a subset analysis of 50 patients who obtained a PET-CT at progression, the median SUVmax for patients who would develop RT was 15.2 (n = 30, range: 4.0-46.3) versus those patients who did not develop RT with a SUVmax of 7.7 (n = 20, range: 2.3-27.2) (p = .0030). Median OS from date of RT was 4.0 months, suggesting that prognosis for RT remains poor. A lymph node biopsy to rule out RT should be considered in patients who received ibrutinib who progress on treatment, have an elevated LDH, or progress with lymphadenopathy without lymphocytosis.
Advances in Multimodality Imaging in Cardio-Oncology
Authors: Lauren A. Baldassarre, Sarju Ganatra, Juan Lopez-Mattei, Eric H. Yang, Vlad G. Zaha, Timothy C. Wong, Chadi Ayoub, Jeanne M. DeCara, Susan Dent, Anita Deswal, Arjun K. Ghosh, Mariana Henry, Abhishek Khemka, Monika Leja, Lawrence Rudski, Hector R. Villarraga, Jennifer E. Liu, Ana Barac, Marielle Scherrer-Crosbie
Journal: Journal of the American College of Cardiology (2022)
Impact of Clonal Hematopoiesis in Patients With Cardiogenic Shock Complicating Acute Myocardial Infarction
Authors: Matthias Böhme, Steffen Desch, Maciej Rosolowski, Markus Scholz, Knut Krohn, Petra Büttner, Michael Cross, Janine Kirchberg, Karl-Philipp Rommel, Janine Pöss, Anne Freund, Ronny Baber, Berend Isermann, Uta Ceglarek, Klaus H. Metzeler, Uwe Platzbecker, Holger Thiele
Journal: Journal of the American College of Cardiology (2022)
Long-Term Changes in Cardiac Structure and Function Following Bariatric Surgery
Authors: Hidemi Sorimachi, Masaru Obokata, Kazunori Omote, Yogesh N.V. Reddy, Naoki Takahashi, Katlyn E. Koepp, Arnold C.T. Ng, Oliver J. Rider, Barry A. Borlaug
Journal: Journal of the American College of Cardiology (2022)
Dose-Response to Sacubitril/Valsartan in Patients With Heart Failure and Reduced Ejection Fraction
Authors: Reza Mohebi, Yuxi Liu, Ileana L Piña, Margaret F Prescott, Javed Butler, G Michael Felker, Jonathan H Ward, Scott D Solomon, James L Januzzi
Journal: Journal of the American College of Cardiology (2022)

Doses of sacubitril/valsartan (Sac/Val) achieved in clinical trials of heart failure with reduced ejection fraction (HFrEF) are often not reached in clinical practice.The purpose of this study was to investigate associations among Sac/Val doses and changes in prognostic biomarkers, health status, and cardiac remodeling among individuals with HFrEF through 12 months of treatment with Sac/Val administered per usual care.A total of 794 persons with HFrEF (ejection fraction [EF] ≤40%) were categorized according to average daily doses of Sac/Val divided into tertiles. Change from baseline to 12 months in biomarkers (N-terminal pro-B-type natriuretic peptide, high-sensitivity cardiac troponin T, soluble ST2, atrial natriuretic peptide, urinary cyclic guanosine monophosphate), Kansas City Cardiomyopathy Questionnaire-23 scores, and parameters of cardiac reverse remodeling (left ventricular EF, indexed left atrial and ventricular volumes, and E/e') were assessed.The average daily dose was 112 mg in Tertile 1 (low dose), 342 mg in Tertile 2 (moderate dose), and 379 mg in Tertile 3 (high dose). Similar changes in prognostic biomarkers were observed in all dose tertiles. Gains in Kansas City Cardiomyopathy Questionnaire-23 scores were comparable regardless of dose category. Consistent reverse cardiac remodeling in all dose categories occurred; the median absolute left ventricular EF improvement across HF dose groups was 9.3%, 8.7%, and 10.2%, for low, moderate, and high doses, respectively; similar improvements in left atrial and ventricular volumes and E/e' were also observed across dose categories.Among patients with HFrEF, similar improvement in prognostic biomarkers, health status, and cardiac remodeling were observed across various Sac/Val doses. (Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes [PROVE-HF]; NCT02887183.
Clinical features and outcomes of hospitalized patients with COVID-19 during the Omicron wave in Shanghai, China
Authors: Bin Wang, Yuefeng Yu, Yuetian Yu, Ningjian Wang, Fengling Chen, Boren Jiang, Yi Chen, Junfeng Zhang, Jianren Liu, Haiya Wang, Feng Ding, Wenchuan Zhang, Yuming Fang, Xiangjun Meng, Youguo Ying, Liu He, Bin Jiang, Xiaofeng Tao, Weining Xiong, Changqian Wang, Hao Wu, Yingli Lu
Journal: Journal of Infection (2022)
A shear-thinning, ROS-scavenging hydrogel combined with dental pulp stem cells promotes spinal cord repair by inhibiting ferroptosis
Authors: Yibo Ying, Zhiyang Huang, Yurong Tu, Qiuji Wu, Zhaoyu Li, Yifan Zhang, Huilei Yu, Annian Zeng, Hanzhi Huang, Jiahui Ye, Weiyang Ying, Min Chen, Zhiyi Feng, Ziyue Xiang, Qingsong Ye, Sipin Zhu, Zhouguang Wang
Journal: Bioactive Materials (2022)

Spinal cord injury (SCI) is a serious clinical disease. Due to the deformability and fragility of the spinal cord, overly rigid hydrogels cannot be used to treat SCI. Hence, we used TPA and Laponite to develop a hydrogel with shear-thinning ability. This hydrogel exhibits good deformation, allowing it to match the physical properties of the spinal cord; additionally, this hydrogel scavenges ROS well, allowing it to inhibit the lipid peroxidation caused by ferroptosis. According to the in vivo studies, the TPA@Laponite hydrogel could synergistically inhibit ferroptosis by improving vascular function and regulating iron metabolism. In addition, dental pulp stem cells (DPSCs) were introduced into the TPA@Laponite hydrogel to regulate the ratios of excitatory and inhibitory synapses. It was shown that this combination biomaterial effectively reduced muscle spasms and promoted recovery from SCI.
Gut bacterial aromatic amine production: aromatic amino acid decarboxylase and its effects on peripheral serotonin production
Authors: Yuta Sugiyama, Yumiko Mori, Misaki Nara, Yusuke Kotani, Emiko Nagai, Hiroki Kawada, Mayu Kitamura, Rika Hirano, Hiromi Shimokawa, Akira Nakagawa, Hiromichi Minami, Aina Gotoh, Mikiyasu Sakanaka, Noriho Iida, Takashi Koyanagi, Takane Katayama, Shigefumi Okamoto, Shin Kurihara
Journal: Gut Microbes (2022)

Colonic luminal aromatic amines have been historically considered to be derived from dietary source, especially fermented foods; however, recent studies indicate that the gut microbiota serves as an alternative source of these amines. Herein, we show that five prominent genera of Firmicutes (Blautia, Clostridium, Enterococcus, Ruminococcus, and Tyzzerella) have the ability to abundantly produce aromatic amines through the action of aromatic amino acid decarboxylase (AADC). In vitro cultivation of human fecal samples revealed that a significant positive correlation between aadc copy number of Ruminococcus gnavus and phenylethylamine (PEA) production. Furthermore, using genetically engineered Enterococcus faecalis-colonized BALB/cCrSlc mouse model, we showed that the gut bacterial aadc stimulates the production of colonic serotonin, which is reportedly involved in osteoporosis and irritable bowel syndrome. Finally, we showed that human AADC inhibitors carbidopa and benserazide inhibit PEA production in En. faecalis.
Expedient secondary functions of flexible piezoelectrics for biomedical energy harvesting
Authors: Yuan Wang, Min Hong, Jeffrey Venezuela, Ting Liu, Matthew Dargusch
Journal: Bioactive Materials (2022)

Flexible piezoelectrics realise the conversion between mechanical movements and electrical power by conformally attaching onto curvilinear surfaces, which are promising for energy harvesting of biomedical devices due to their sustainable body movements and/or deformations. Developing secondary functions of flexible piezoelectric energy harvesters is becoming increasingly significant in recent years via aiming at issues that cannot be addressed or mitigated by merely increasing piezoelectric efficiencies. These issues include loose interfacial contact and pucker generation by stretching, power shortage or instability induced by inadequate mechanical energy, and premature function degeneration or failure caused by fatigue fracture after cyclic deformations. Herein, the expedient secondary functions of flexible piezoelectrics to mitigate above issues are reviewed, including stretchability, hybrid energy harvesting, and self-healing. Efforts have been devoted to understanding the state-of-the-art strategies and their mechanisms of achieving secondary functions based on piezoelectric fundamentals. The link between structural characteristic and function performance is unravelled by providing insights into carefully selected progresses. The remaining challenges of developing secondary functions are proposed in the end with corresponding outlooks. The current work hopes to help and inspire future research in this promising field focusing on developing the secondary functions of flexible piezoelectric energy harvesters.
Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis
Authors: Eli Muchtar, Angela Dispenzieri, Brendan Wisniowski, Giovanni Palladini, Paolo Milani, Giampaolo Merlini, Stefan Schönland, Kaya Veelken, Ute Hegenbart, Susan M. Geyer, Shaji K. Kumar, Efstathios Kastritis, Meletios A. Dimopoulos, Michaela Liedtke, Ronald Witteles, Vaishali Sanchorawala, Raphael Szalat, Heather Landau, Erica Petrlik, Suzanne Lentzsch, Alexander Coltoff, Joan Bladé, Maria Teresa Cibeira, Oliver Cohen, Darren Foard, Ashutosh Wechalekar, Morie A. Gertz
Journal: Journal of Clinical Oncology (2022)

PURPOSE Binary cardiac response assessment using cardiac biomarkers is prognostic in light chain amyloidosis. Previous studies suggested four-level cardiac responses using N-terminal prohormone of brain natiuretic peptide improves prognostic prediction. This study was designed to validate graded cardiac response criteria using N-terminal prohormone of brain natiuretic peptide/brain natiuretic peptide. PATIENTS AND METHODS This retrospective, multicenter study included patients with light chain amyloidosis who achieved at least a hematologic partial response (PR) and were evaluable for cardiac response. Four response criteria were tested on the basis of natriuretic peptide response depth: cardiac complete response (CarCR), cardiac very good partial response (CarVGPR), cardiac PR (CarPR), and cardiac no response (CarNR). Response was classified as best response and at fixed time points (6, 12, and 24 months from therapy initiation). The study primary outcome was overall survival. RESULTS 651 patients were included. Best CarCR, CarVGPR, CarPR, and CarNR were achieved in 16%, 26.4%, 22.9%, and 34.7% of patients, respectively. Patients in cardiac stage II were more likely to achieve CarCR than patients in cardiac stage IIIA and IIIB (22% v 13.5% v 3.2%; P &lt; .001). A deeper cardiac response was associated with a longer survival (5-year overall survival 93%, 79%, 65%, and 33% for CarCR, CarVGPR, CarPR, and CarNR, respectively; P &lt; .001). Fixed time-point analyses and time-varying covariates Cox regression analysis, to minimize survivorship bias, affirmed the independent survival advantage of deeper cardiac responses. Four-level response performed better than two-level response as early as 12 months from therapy initiation. CONCLUSION Graded cardiac response criteria allow better assessment of cardiac improvement compared with the traditional binary response system. The study re-emphasizes the importance of early diagnosis, which increases the likelihood of deep cardiac responses.
Multiomic analysis of papillary thyroid cancers identifies BAIAP2L1-BRAF fusion and requirement of TRIM25, PDE5A and PKCδ for tumorigenesis
Authors: Emilie Renaud, Kristina Riegel, Rossana Romero, Kushal Suryamohan, Ute Distler, Stefan Tenzer, Arno Schad, Thomas J. Musholt, Krishnaraj Rajalingam
Journal: Molecular Cancer (2022)

Papillary thyroid carcinoma (PTC) is one of the most common forms of thyroid cancer with a cure rate of over 90% after surgery. However, aggressive forms may still occur, and personalized therapeutic strategies are increasingly required.We performed integrated genomic and proteomic analysis of PTC tumor samples from patients who did not harbor BRAF or RAS mutations. We validate the analysis and present in-depth molecular analysis of the identified genetic rearrangement by employing biochemical and cell biological assays. Finally, we employ 3D spheroid models, loss of function studies and chemical inhibitors to target the hitherto upregulated factors. The data are analysed with appropriate statistical tests which are mentioned in the legends section.In a 23-year-old patient with thyroiditis, we identified a novel rearrangement leading to a BAIAP2L1-BRAF fusion that transforms immortalized human thyroid cells in a kinase and CC-domain dependent manner. Moreover, quantitative proteomic analysis of the same patient samples revealed the upregulation of several proteins including the Ubiquitin E3 ligase TRIM25, PDE5A, and PKCδ. Further, in a cohort of PTC patients, we observed higher expression of TRIM25 and PKCδ in the tumor and metastatic lesions, when compared to the matched normal tissue. Inhibition of TRIM25, PDE5A and PKCδ with small molecules or RNA interference affected not only viability and proliferation of BAIAP2L1-BRAF transformed cells, but also the viability, growth and invasion of corresponding 3D spheroid cultures.Apart from unveiling a novel oncogenic BRAF fusion in PTCs, our data may open a novel avenue of therapeutic targeting in human PTCs.
Longitudinal Changes and Predictive Value of Choroidal Thickness for Myopia Control after Repeated Low-Level Red-Light Therapy
Authors: Ruilin Xiong, Zhuoting Zhu, Yu Jiang, Wei Wang, Jian Zhang, Yanping Chen, Gabriella Bulloch, Yixiong Yuan, Shiran Zhang, Meng Xuan, Junwen Zeng, Mingguang He
Journal: Ophthalmology (2022)

To evaluate longitudinal changes in macular choroidal thickness (mCT) in myopic children treated for 1 year with repeated low-level red-light (RLRL) therapy and their predictive value for treatment efficacy on myopia control.A secondary analysis of data from a multicenter, randomized controlled trial (RCT; NCT04073238).Myopic children aged 8-13 years who participated in the RCT at 2 of 5 sites where mCT measurements were available.Repeated low-level red-light therapy was delivered using a home-use desktop light device that emitted red-light at 650 nm. Choroidal thickness was measured by SS-OCT at baseline and 1-, 3-, 6-, and 12-month follow-ups. Visual acuity, axial length (AL), cycloplegic spherical equivalent refraction (SER), and treatment compliance were measured.Changes in mCT at 1, 3, 6, and 12 months relative to baseline, and their associations with myopia control.A total of 120 children were included in the analysis (RLRL group: n = 60; single-vision spectacle [SVS] group: n = 60). Baseline characteristics were well balanced between the 2 groups. In the RLRL group, changes in mCT from baseline remained positive over 1 year, with a maximal increase of 14.755 μm at 1 month and gradually decreasing from 5.286 μm at 3 months to 1.543 μm at 6 months, finally reaching 9.089 μm at 12 months. In the SVS group, mCT thinning was observed, with changes from baseline of -1.111, -8.212, -10.190, and -10.407 μm at 1, 3, 6, and 12 months, respectively. Satisfactory myopia control was defined as annual progression rates of less than 0, 0.05, or 0.10 mm for AL and less than 0, 0.25, or 0.50 diopters for SER. Models that included mCT changes at 3 months alone had acceptable predictive discrimination of satisfactory myopia control over 12 months, with areas under the curve of 0.710-0.786. The predictive performance of the models did not significantly improve after adding age, gender, and baseline AL or SER.This analysis from a multicenter RCT found RLRL induced sustained choroidal thickening over the full course of treatment. Macular choroidal thickness changes at 3 months alone can predict 12-month myopia control efficacy with reasonable accuracy.Proprietary or commercial disclosure may be found after the references.
Mapping of Spatiotemporal Auricular Electrophysiological Signals Reveals Human Biometric Clusters
Authors: Qingyun Huang, Cong Wu, Senlin Hou, Kuanming Yao, Hui Sun, Yufan Wang, Yikai Chen, Junhui Law, Mingxiao Yang, Ho‐yin Chan, Vellaisamy A. L. Roy, Yuliang Zhao, Dong Wang, Enming Song, Xinge Yu, Lixing Lao, Yu Sun, Wen Jung Li
Journal: Advanced Healthcare Materials (2022)

Abstract Underneath the ear skin there are rich vascular network and sensory nerve branches. Hence, the 3D mapping of auricular electrophysiological signals can provide new biomedical perspectives. However, it is still extremely challenging for current sensing techniques to cover the entire ultra‐curved auricle. Here, a 3D graphene‐based ear‐conformable sensing device with embedded and distributed 3D electrodes for full‐auricle physiological monitoring is reported. As a proof‐of‐concept, spatiotemporal auricular electrical skin resistance (AESR) mapping is demonstrated for the first time, and human subject‐specific AESR distributions are observed. From the data of more than 30 ears (both right and left ears), the auricular region‐specific AESR changes after cycling exercise are observed in 98% of the tests and are clustered into four groups via machine learning‐based data analyses. Correlations of AESR with heart rate and blood pressure are also studied. This 3D electronic platform and AESR‐based biometrical findings show promising biomedical applications.
Autophagy inhibition impairs leukemia stem cell function in FLT3-ITD AML but has antagonistic interactions with tyrosine kinase inhibition
Authors: Shaowei Qiu, Harish Kumar, Chengcheng Yan, Hui Li, Andrew J. Paterson, Nicholas R. Anderson, Jianbo He, Jing Yang, Min Xie, David K. Crossman, Rui Lu, Robert S. Welner, Ravi Bhatia
Journal: Leukemia (2022)
How can I make the NHS greener?
Authors: Adele Waters
Journal: BMJ (2022)

Adele Waters hears what doctors can do to make their specialties greener Eleanor Damm, co-chair of the environmental sustainability workgroup, Intensive Care Society UK, says, “What does ‘green intensive care practice’ look like? Well, firstly, let’s stop calling it ‘green.’ “Sustainability should be a core consideration of how we deliver care—not an afterthought. “The NHS produces 5% of the UK’s greenhouse gases so there is a clear need to embed environmental governance in each critical care unit. That means we have plenty in our intray: